301096 百诚医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.120-2.00410.5288.0898.358
总资产报酬率 ROA (%)0.082-1.4278.2436.6336.233
投入资产回报率 ROIC (%)0.086-1.5428.9667.0626.632

边际利润分析
销售毛利率 (%)50.73551.98265.52867.37367.265
营业利润率 (%)1.109-4.28929.19331.05731.789
息税前利润/营业总收入 (%)3.441-3.97226.97724.54632.013
净利润/营业总收入 (%)0.932-6.60026.73531.94629.646

收益指标分析
经营活动净收益/利润总额(%)-107.78122.084102.44990.73396.330
价值变动净收益/利润总额(%)43.28815.506-0.036-2.081-0.547
营业外收支净额/利润总额(%)5.5064.624-0.4541.185-0.035

偿债能力分析
流动比率 (X)1.8202.0091.9005.5384.708
速动比率 (X)1.6041.7781.7905.3114.660
资产负债率 (%)33.35530.68426.84515.27320.756
带息债务/全部投入资本 (%)27.83422.86115.2123.57012.664
股东权益/带息债务 (%)249.431321.431529.9792,540.417662.769
股东权益/负债合计 (%)199.806225.906272.510554.820381.801
利息保障倍数 (X)1.518-7.575-12.943-3.566135.989

营运能力分析
应收账款周转天数 (天)221.043126.01561.82067.05353.508
存货周转天数 (天)210.612126.45481.71580.74838.888